181 related articles for article (PubMed ID: 19057796)
1. [FDG-PET in Hodgkin lymphoma].
Kobe C; Dietlein M; Mauz-Körholz C; Engert A; Borchmann P; Sabri O; Schober O; Schicha H; Kluge R
Nuklearmedizin; 2008; 47(6):235-8; quiz N75-6. PubMed ID: 19057796
[TBL] [Abstract][Full Text] [Related]
2. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Dietlein M; Franklin J; Markova J; Lohri A; Amthauer H; Klutmann S; Knapp WH; Zijlstra JM; Bockisch A; Weckesser M; Lorenz R; Schreckenberger M; Bares R; Eich HT; Mueller RP; Fuchs M; Borchmann P; Schicha H; Diehl V; Engert A
Blood; 2008 Nov; 112(10):3989-94. PubMed ID: 18757777
[TBL] [Abstract][Full Text] [Related]
4. The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.
Kobe C; Dietlein M; Kriz J; Furth C; Fuchs M; Borchmann P; Engert A; Eich HT
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1419-28. PubMed ID: 20836677
[TBL] [Abstract][Full Text] [Related]
5. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
[TBL] [Abstract][Full Text] [Related]
6. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
[TBL] [Abstract][Full Text] [Related]
7. [Role of FDG-PET in Staging and Therapy of Children with Hodgkin Lymphoma].
Kluge R; Körholz D
Klin Padiatr; 2011 Nov; 223(6):315-9. PubMed ID: 22012607
[TBL] [Abstract][Full Text] [Related]
8. Change of initial staging at early remission evaluation with FDG-PET/CT in Hodgkin lymphoma: a report of two cases.
Molin D; Hagberg H; Suurküla M; Aström G
Acta Oncol; 2010 May; 49(4):526-8. PubMed ID: 20397779
[No Abstract] [Full Text] [Related]
9. Response-Adapted Treatment Strategies in Hodgkin Lymphoma Using PET Imaging.
Bair SM; Svoboda J
PET Clin; 2019 Jul; 14(3):353-368. PubMed ID: 31084775
[TBL] [Abstract][Full Text] [Related]
10. Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.
Kurch L; Hasenclever D; Kluge R; Georgi T; Tchavdarova L; Golombeck M; Sabri O; Eggert A; Brenner W; Sykora KW; Bengel FM; Rossig C; Körholz D; Schäfers M; Feuchtinger T; Bartenstein P; Ammann RA; Krause T; Urban C; Aigner R; Gattenlöhner S; Klapper W; Mauz-Körholz C
Pediatr Blood Cancer; 2019 Mar; 66(3):e27539. PubMed ID: 30426671
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Lymphoma Therapy Using (18)F-FDG PET.
Lowe VJ; Wiseman GA
J Nucl Med; 2002 Aug; 43(8):1028-30. PubMed ID: 12163627
[No Abstract] [Full Text] [Related]
12. An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma.
Adams HJA; Kwee TC
Semin Oncol; 2017 Dec; 44(6):404-419. PubMed ID: 29935902
[TBL] [Abstract][Full Text] [Related]
13. Does interim 18F-FDG-PET response-adapted therapy really benefit advanced-stage Hodgkin lymphoma patients?
Adams HJ; Kwee TC
Nucl Med Commun; 2016 Dec; 37(12):1333-1334. PubMed ID: 27501435
[No Abstract] [Full Text] [Related]
14. Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: a randomized study caveat.
Yahalom J
Leuk Lymphoma; 2007 Sep; 48(9):1667-9. PubMed ID: 17786699
[No Abstract] [Full Text] [Related]
15. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score.
Milgrom SA; Dong W; Akhtari M; Smith GL; Pinnix CC; Mawlawi O; Rohren E; Garg N; Chuang H; Yehia ZA; Reddy JP; Gunther JR; Khoury JD; Suki T; Osborne EM; Oki Y; Fanale M; Dabaja BS
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):333-338. PubMed ID: 28068241
[TBL] [Abstract][Full Text] [Related]
17. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
18. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
19. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
Delbeke D; Stroobants S; de Kerviler E; Gisselbrecht C; Meignan M; Conti PS
Oncologist; 2009; 14 Suppl 2():30-40. PubMed ID: 19819922
[TBL] [Abstract][Full Text] [Related]
20. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
Hutchings M
Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
